Literature DB >> 35956125

Special Issue "Clinical Epidemiology of Diabetes and Its Complications".

Tatsuya Fukuda1,2.   

Abstract

The purpose of this Special Issue, "Clinical Epidemiology of Diabetes and Its Complications" is to bring more attention to diabetes and its complications and share the latest findings with the medical community [...].

Entities:  

Year:  2022        PMID: 35956125      PMCID: PMC9369457          DOI: 10.3390/jcm11154510

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.964


The purpose of this Special Issue, “” is to bring more attention to diabetes and its complications and share the latest findings with the medical community. Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged at the end of 2019, spread rapidly worldwide, and continues to remain a public health crisis as of 2022 [1]. Notably, the COVID-19 pandemic apparently makes glycemic control more difficult in patients with diabetes. A study from India compared 282 patients who were newly diagnosed with diabetes during the COVID-19 pandemic and 273 patients who were newly diagnosed with diabetes before the pandemic [2]; this study found that patients diagnosed with diabetes during the COVID-19 pandemic had higher levels of fasting and postprandial blood glucose and glycated hemoglobin compared with those diagnosed before the pandemic. Additionally, another systematic review elaborated on the possibility of COVID-19 lockdowns worsening glycemic control in patients with type 2 diabetes [3], potentially, in part, due to a reduction in physical activity and limited access to a healthy diet. Furthermore, the pandemic made it difficult for patients with diabetes to regularly visit hospitals due to fear of contracting the virus, thereby hampering their ability to adequately manage not only their blood glucose levels but also the associated complications. For example, it has been reported that regular screening and early treatment for diabetic retinopathy could prevent vision loss [4,5,6,7]; however, the COVID-19 pandemic led to a decrease in hospital visits and treatment, presumably worsening ophthalmologic prognosis [8]. The diagnosis and treatment of diabetic complications, including retinopathy, are highly dependent on the medical equipment in hospitals; therefore, it may be difficult to manage diabetic complications through telemedicine, even though it has gained traction during the COVID-19 epidemic. At present, diabetes is widely regarded as a risk factor for serious outcomes in COVID-19, especially among those with poor glycemic control, because they are vulnerable to severe COVID-19 [9]. A large-scale study from the United Kingdom reported a 1.8-fold greater risk of death from COVID-19 among individuals with diabetes compared with that among those without diabetes [10], and showed that the presence of diabetic complications, including cardiovascular disease and nephropathy, was independently associated with risk of death due to COVID-19. Similarly, a cohort study in the entire population of Scotland also reported diabetic retinopathy and nephropathy to be independently associated with fatal or critical-care-requiring cases of COVID-19 [11]. Thus, these studies indicate that management of diabetic complications is as important as glycemic control for the prevention of severe COVID-19. These findings imply that patients with diabetes are at risk of severe sequelae and are thus required to achieve better control of not only their blood glucose levels but also complications, especially in situations that are more difficult to manage than they were before the COVID-19 pandemic. Therefore, physicians have been asked to more carefully manage blood glucose levels and diagnose and treat complications earlier, in a manner that lowers the risk of coronavirus exposure as much as possible. The first article in this issue, by Saunajoki et al. [12], which is a cross-sectional survey of 496 individuals without a history of either prediabetes or diabetes, demonstrated that plasma glucose levels measured 1 h after a 75 g oral glucose tolerance test were apparently the best glycemic predictor of the presence of albuminuria. This finding may suggest that the blood glucose level 1 h after a 75 g oral glucose tolerance test is predictive of greater risk of kidney disease. The present Special Issue aims to provide a broad updated spectrum of knowledge of the pathogenetic, diagnostic, and therapeutic aspects of diabetes and its complications, and treatment strategies that remain effective in the COVID-19 pandemic.
  11 in total

1.  Preliminary report on effects of photocoagulation therapy. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1976-04       Impact factor: 5.258

2.  Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration.

Authors:  Eser Kirkizlar; Nicoleta Serban; Jennifer A Sisson; Julie L Swann; Claire S Barnes; Michael D Williams
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

3.  Incidence Density and Risk Factors of Diabetic Retinopathy Within Type 2 Diabetes: A Five-Year Cohort Study in China (Report 1).

Authors:  Lei Liu; Jingyang Wu; Song Yue; Jin Geng; Jie Lian; Weiping Teng; Desheng Huang; Lei Chen
Journal:  Int J Environ Res Public Health       Date:  2015-07-10       Impact factor: 3.390

4.  Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland.

Authors:  Stuart J McGurnaghan; Amanda Weir; Jen Bishop; Sharon Kennedy; Luke A K Blackbourn; David A McAllister; Sharon Hutchinson; Thomas M Caparrotta; Joseph Mellor; Anita Jeyam; Joseph E O'Reilly; Sarah H Wild; Sara Hatam; Andreas Höhn; Marco Colombo; Chris Robertson; Nazir Lone; Janet Murray; Elaine Butterly; John Petrie; Brian Kennon; Rory McCrimmon; Robert Lindsay; Ewan Pearson; Naveed Sattar; John McKnight; Sam Philip; Andrew Collier; Jim McMenamin; Alison Smith-Palmer; David Goldberg; Paul M McKeigue; Helen M Colhoun
Journal:  Lancet Diabetes Endocrinol       Date:  2020-12-23       Impact factor: 32.069

5.  Glycemic parameters in patients with new-onset diabetes during COVID-19 pandemic are more severe than in patients with new-onset diabetes before the pandemic: NOD COVID India Study.

Authors:  Amerta Ghosh; Ranjit Mohan Anjana; Coimbatore Subramanian Shanthi Rani; Saravanan Jeba Rani; Ritesh Gupta; Alka Jha; Vimal Gupta; Mohammad Shafi Kuchay; Atul Luthra; Suhail Durrani; Koel Dutta; Kanika Tyagi; Ranjit Unnikrishnan; Brijendra Kumar Srivastava; Muthu Ramu; Nadiminty Ganapathi Sastry; Prasanna Kumar Gupta; Ganesan Umasankari; Ramamoorthy Jayashri; Viswanathan Mohan; Anoop Misra
Journal:  Diabetes Metab Syndr       Date:  2020-12-29

Review 6.  The Impact of COVID-19 on Diabetic Retinopathy Monitoring and Treatment.

Authors:  Ishrat Ahmed; T Y Alvin Liu
Journal:  Curr Diab Rep       Date:  2021-09-08       Impact factor: 4.810

7.  Elevated One-Hour Post-Load Glucose Is Independently Associated with Albuminuria: A Cross-Sectional Population Study.

Authors:  Anni Saunajoki; Juha Auvinen; Aini Bloigu; Jouko Saramies; Jaakko Tuomilehto; Hannu Uusitalo; Esko Hussi; Henna Cederberg-Tamminen; Kadri Suija; Sirkka Keinänen-Kiukaanniemi; Markku Timonen
Journal:  J Clin Med       Date:  2022-07-15       Impact factor: 4.964

Review 8.  Diabetes and COVID19: a bidirectional relationship.

Authors:  Ranjit Unnikrishnan; Anoop Misra
Journal:  Nutr Diabetes       Date:  2021-06-23       Impact factor: 5.097

9.  A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010.

Authors:  Gerald Liew; Michel Michaelides; Catey Bunce
Journal:  BMJ Open       Date:  2014-02-12       Impact factor: 2.692

10.  Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study.

Authors:  Emma Barron; Chirag Bakhai; Partha Kar; Andy Weaver; Dominique Bradley; Hassan Ismail; Peter Knighton; Naomi Holman; Kamlesh Khunti; Naveed Sattar; Nicholas J Wareham; Bob Young; Jonathan Valabhji
Journal:  Lancet Diabetes Endocrinol       Date:  2020-08-13       Impact factor: 32.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.